Home
Stampa
HomeStampa
HomeStampa
13:30 - 16:00 | Special Session
Incontro scuole RaccontART
17:00 - 18:00 | Satellite Symposium
Defining new patient-centric goals to improve long-term treatment success in HIV
18:00 - 20:00
ICAR 2022 Opening Session
14:30 - 16:30 | Pre-Conference advanced course
Focus on viral resistance and variability
14:30 - 16:30 | Pre-Conference advanced course
Clinical and point of care diagnostics for STIs in a PrEP service
14:30 - 16:30 | Pre-Conference advanced course
New psychoactive substances and chemsex. David Stuart Course
Special Session
Incontro scuole RaccontART
Con la sponsorizzazione di: 
Special Session
Incontro scuole RaccontART
ICAR dedica particolare attenzione alle tematiche legate alla prevenzione e al coinvolgimento della società civile e lancia, come ogni anno, il Contest Artistico RaccontART, giunto all'ottava edizione e destinato agli studenti degli Istituti Scolastici Superiori. RaccontART rappresenta un'occasione unica e preziosa di formazione e informazione in tema di HIV, Infezioni Sessualmente Trasmissibili e Covid-19. Questa sessione è dedicata alla presentazione delle Opere finaliste in concorso, selezionate dalle Giurie Artistica e Tecnico-Scientifica. I primi tre classificati verranno premiati durante l'Opening Session.
Chairs: A. Caraglia, F. Ceccherini - Silberstein, D. Zagato
Satellite Symposium
Defining new patient-centric goals to improve long-term treatment success in HIV
Con la sponsorizzazione non condizionante di:
Satellite Symposium
Defining new patient-centric goals to improve long-term treatment success in HIV
Although 30 years of research and pharmacological innovation have transformed HIV infection into a chronic disease, the persistence of issues related to direct and indirect harm of the virus, life-long ART exposure, higher risk of comorbidities and host peculiarities mean that life-expectancy and QoL of PLWH are still significantly lower compared with general population. In this scenario, the definition of a new and broader concept of long-term treatment success able to meet not only the clinical goals but also needs and expectations of PLWH, becomes even more crucial. A "tailored" approach based on the complexities of the individual (often not manifested) together with the availability of ARVs optimized in terms of efficacy, genetic barrier, forgiveness, tolerability, and convenience are probably the key to reach this ambitious goal. Through an interactive talk, experts will discuss on current challenges and available strategies to fill these gaps, also with the support of real-life data.
Chair: G. Di Perri
| 17.00 - 17.15 |
How to define long-term treatment success for PLWH and which attributes are requested to ARV?
M. Andreoni |
| 17.15 - 17.55 |
Round-table discussion on how to improve outcomes with current antiretroviral therapy: Conductor: A. Gori - How important are high genetic barrier, forgiveness and adherence? A. Calcagno - How to optimize the long-term treatment outcomes in experienced patients? R. Gagliardini - What is the added value of real-world evidence? L. Taramasso |
| 17.55 - 18.00 |
Take-home messages and conclusions
G. Di Perri |
ICAR 2022 Opening Session
ICAR 2022 Opening Session
Conduce: T. Cartolano
Chairs: A. Antinori, M.G.L. Cernuschi, F. Maggiolo, M. Zazzi
| 18.00 - 18.20 | Introducing ICAR 2022. Chairs and Authorities' welcome addresses |
| 18.20 - 18.40 | RaccontART contest Awards |
| 18.40 - 19.10 |
Mauro Moroni Memorial Lecture COVID-19 past, present and future. Will covid ever retire?
M. Andreoni |
| 19.10 - 19.40 |
HIV as a chronic disease: myth or truth?
F. Maggiolo, S. Mattioli |
| 19.40 - 20.00 | Opening session closing remarks |
Pre-Conference advanced course
Focus on viral resistance and variability
Pre-Conference advanced course
Focus on viral resistance and variability
RNA viruses show a great potential for genetic variation, rapid evolution and adaptation. Genetic variability may affect pathogenesis, epidemiology and the success of antiviral therapy. In the past months, several SARS-CoV-2 variants of concern (VOCs) have emerged and an intense monitoring of their circulation worldwide plays a crucial role not only in surveillance but also as part of containment and mitigation strategies. Different molecular methods to detect and characterize a specific viral variant have been developed. Many of these assays can accurately identify the variants, while others require confirmation by sequencing. Viral genetic variability is also responsible for drug resistance, a well known phenomenon in HIV infection. Despite successful antiretroviral therapy, a minority of people living with HIV (PLWH) still have difficulty in achieving and maintaining virological suppression, mainly due to HIV drug resistance, and a small group of them harbor multi-drug resistant viruses. In this scenario, the emergence of drug resistance mutations to the latest antiretroviral drugs should be carefully investigated. Nowadays, more than 90% of PLWH have undetectable viral load. ART optimization or simplification in this clinical setting can be critical, especially when previous ART history is complex or unknown. The current transition from Sanger sequencing to Next Generation Sequencing to detect archived HIV drug resistance mutations could offer novel treatment-relevant insights and improve the management of virologically suppressed patients.
Chairs: R. Gagliardini, V. Micheli, O. Turriziani
| 14.30 - 15.00 |
HIV drug resistance mutations to new antiretroviral drugs
F. Saladini |
| 15.00 - 15.30 |
Detection of archived HIV drug resistance mutations in virologically suppressed individuals by different genotyping techniques: from Sanger to NGS
M. Santoro |
| 15.30 - 16.00 |
Molecular assays to characterize SARS-CoV-2 viral variants
F. Caccuri |
| 16.00 - 16.30 | Discussion on Course issues |
Pre-Conference advanced course
Clinical and point of care diagnostics for STIs in a PrEP service
Pre-Conference advanced course
Clinical and point of care diagnostics for STIs in a PrEP service
The syndromic approach for the management of sexually transmitted infections (STIs) relies on the assessment of patient's general complaints: clinical evaluation represents the best and fastest way to choose the appropriate treatment. Laboratory tests provide the correct etiologic diagnosis but turn-around times could be an issue in a clinic dedicated to PrEP care, where a high burden of STIs and heavily interconnected sexual networks require a rapid handling. Overtreatment and spread of antimicrobial resistance are additional drawbacks if microbial diagnosis is not readily available. Point-of-care diagnostics could be helpful both in hospital- and community-based services for rapid diagnosis and epidemiological monitoring of people in PrEP.
Chairs: V. Mazzotta, R. Rossotti
| 14.30 - 15.00 |
Traditional versus point of care diagnostics for STIs: pros and cons
A. Nava |
| 15.00 - 15.30 |
Clinical approach to the diagnosis of STIs, treatment criteria and concerns about microbial resistance
S. Pittalis |
| 15.30 - 16.00 |
Management of STIs diagnosis in a community-based, peer-run PrEP service
V. Ferrara |
| 16.00 - 16.30 | Discussion on Course issues |
Pre-Conference advanced course
New psychoactive substances and chemsex. David Stuart Course
Pre-Conference advanced course
New psychoactive substances and chemsex. David Stuart Course
Chemsex can be defined as the use of specific drugs (chems), in a sexualized context, by gay men and other men who have sex with men. Chemsex is associated with peculiar socio-cultural aspects of MSM sexuality. Chems use also varies in different geographical areas according to availability, affordability or other circumstances. Initially three substances only have been named as chems. Other substances now are added to chems. Chemsex adds ritual aspects, often driven by dating networks, to MSM sexual behavior. It is a complex phenomenon that involves different areas and can have different impact on different people and require different approaches. There is a need for more information about substances and how to reduce risks associated with their use, while for more problematic aspects (social, behavioral, psychologic, psychiatric, and medical), a therapeutic group's experience - supervised by a psychotherapist - can be an opportunity to cope with abuse.
Chairs: G. Fracca, M. Lanza
| 14.30 - 14.50 |
Definition and evolution of sexualized psychoactive substances' use in Italy
F.M. Nimbi |
| 14.50 - 15.10 |
MPDV and free coke as chems. Harm reduction-
M. Lanza |
| 15.10 - 15.30 |
Chemsex as social ritual among MSM
G.M. Corbelli |
| 15.30 - 15.50 |
Chemsex addiction: dealing with the unconscious as a pathway for treatment
G. Fracca |
| 15.50 - 16.30 | Discussion on Course issues |
09:00 - 10:00
Keynote Lectures
10:05 - 11:05 | Sponsored Symposium
Being pioneers of a new paradigm: what have we learned so far?
11:10 - 12:10 | Satellite Symposium
HIV: act in the present and challenge the future
12:15 - 13:15 | Symposium
New Insights and Challenges on Hepatitis and HIV Co-infections
14:30 - 15:30 | Sponsored Symposium
Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF
15:35 - 16:35 | Symposium
At the edge of PREP
16:40 - 17:40 | Symposium
Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates
17:45 - 18:45 | Symposium
Challenges in HIV cure: getting to zero reservoir
10:05 - 11:05 | Oral Communications
PrEP: new data and issues
11:10 - 12:10 | Oral Communications
Immunological efficacy of SARS-CoV-2 vaccine I
12:15 - 13:15 | Expert Meeting
Narrative Medicine applied to Vaccination during Covid-19 pandemic
13:15 - 14:30 | Special Session
How to use U=U to fight stigma
14:30 - 15:30 | Oral Communications
COVID-19: clinical management
15:35 - 16:35 | Oral Communications
Pathogenesis & Immunology
16:40 - 17:40 | Oral Communications
From HIV to SARS-CoV-2
17:45 - 18:45 | Oral Communications
Metabolic alterations: effect of drugs and diseases
10:05 - 11:05 | Satellite Symposium
Hepatitis Delta in HIV/HBV Infected Patients
11:10 - 12:00 | Oral Poster
COVID-19: treatment strategies II
12:15 - 13:15 | Sponsored Symposium
Cabotegravir + rilpivirine long-acting: are we ready for the new era?
13:15 - 14:15 | Oral Communications
Metabolic issues in effective HAART
14:30 - 15:30 | Expert Meeting
The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations
15:35 - 16:35 | Interactive Expert Meeting
Affairs of the heart in HIV: redundant or a key challenge?
16:40 - 17:40 | Expert Meeting
Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies
17:45 - 18:45 | Oral Communications
Special issues in clinical HIV
11:10 - 12:00 | Oral Poster
Treatment of naive PLWH: current strategies and rapid start of ART
13:25 - 14:15 | Oral Poster
Predictors of COVID-19 severity
14:30 - 15:20 | Oral Poster
Viro-immunological correlates of COVID-19 severity
15:35 - 16:25 | Oral Poster
Neuropsychological complications in COVID-19
16:40 - 17:30 | Oral Poster
Cardiovascular diseases, osteoporosis but not only
17:45 - 18:35 | Oral Poster
Measuring HIV stigma and disclosure
10:05 - 10:55 | Oral Poster
COVID-19: treatment strategies I
11:10 - 12:00 | Oral Poster
PrEP: real life experience
12:15 - 13:05 | Oral Poster
Access to test and educational aspects
13:25 - 14:15 | Oral Poster
HCV eradication: general and key populations
14:30 - 15:20 | Oral Poster
Issues on mental health, sexual health and STIs
15:35 - 16:25 | Oral Poster
New issues on dual therapy
16:40 - 17:30 | Oral Poster
Vulnerable and key population: local experiences
17:45 - 18:35 | Oral Poster
Models of COVID-19 pathogenesis and response to vaccination
Keynote Lectures
Keynote Lectures
Chairs: M.G. Di Benedetto, A. Lazzarin
| 09.00 - 09.30 |
Virus spillover
G. Antonelli |
| 09.30 - 10.00 |
Innate immunity and COVID-19
C. Garlanda |
Sponsored Symposium
Being pioneers of a new paradigm: what have we learned so far?
Con il supporto di: 
Sponsored Symposium
Being pioneers of a new paradigm: what have we learned so far?
The life expectancy of people living with HIV (PLHIV) is now close to the one of HIV negative people. This important milestone has been achieved thanks to the continuous evolution of antiretroviral therapy (ART), the basis of which continuous improvement placed on providing optimal therapeutic options for long-term management. In this context, ART therapy has evolved in the direction of 2-drug regimens (2DR), which represent a new paradigm supported by solid evidence from clinical trials confirmed in real-life. In particular, dolutegravir/lamivudine (DTG/3TC) represents an important therapeutic option, both in the initial phase of treatment and in the switch from ARV. Starting from these assumptions, the session will focus on the learnings coming from the validation of this new paradigm which bases its foundations on robust data, and which means having an additional option to personalize treatment for PLHIV naïve and virologically suppressed. Regarding these aspects, the most recent data available for regimens containing dolutegravir and lamivudine (DTG / 3TC; DTG + 3TC) will be discussed.
Chairs: S. Cicalini, R. Gulminetti
| 10.05 - 10.15 | Introduction |
| 10.15 - 10.30 |
The relevance of robust and valuable data
P. Mohammed |
| 10.30 - 10.50 |
The meaning of personalizing treatments
C. Mussini |
| 10.50 - 11.05 | Questions & Answers |
Satellite Symposium
HIV: act in the present and challenge the future
Con la sponsorizzazione non condizionante di: 
Satellite Symposium
HIV: act in the present and challenge the future
Since the introduction of ART there has been increased survival in PLWH; nowadays it is important to answer to needs of every single HIV-positive patient - requiring long-life antiretroviral treatments providing durability and tolerability- but also to consider the challenges raising from HIV-negative at-risk population. The aim of this Symposium is to deepen the challenge coming from the HIV vaccine as public health measure, focusing on clinical and social aspects. Furthermore, it is of utmost importance keep the focus in the present days for discussing the appropriate treatment strategies to adopt in daily practice for improving patients care.
Chairs: A. Cingolani, G.M. Corbelli
| 11.10 - 11.30 |
What we know about HIV Vaccine?
S. Nozza |
| 11.30 - 11.50 |
PI-based learning
S. Rusconi |
| 11.50 - 12.10 | Discussion on Symposium issues |
Symposium
New Insights and Challenges on Hepatitis and HIV Co-infections
Symposium
New Insights and Challenges on Hepatitis and HIV Co-infections
This symposium is aimed at providing new insights on three topics in the field of hepatitis and HIV coinfections. In particular, the first lecture will provide a comprehensive overview on novel anti-HBV drugs, targeting different phases of HBV life cycle, that should go beyond the concept of virological suppression and aim at achieving HBV functional cure. Particular attention will be dedicated to the challenges that virologists and clinicians will have to cope to reach this important end-point. With a decade left to reach the ambitious WHO goals for viral hepatitis elimination, many challenges still remain concerning the need to scale-up HCV testing and expand access to HCV treatment particularly in marginalized populations at risk for HCV infection. The importance of these aspects in elimination efforts, with an emphasis on micro-elimination strategies, will be explored in the second lecture of the symposium. Finally, the third lecture will be dedicated to HIV+CMV coinfection, an intriguing and crucial aspect contributing to HIV pathogenesis. Indeed, persistent CMV replication or reactivation have been demonstrated to fuel HIV reservoir and to exacerbate the process of inflammaging and immune-senescence.
Chairs: S. Babudieri, V. Svicher
| 12.15 - 12.30 |
Novel anti-HBV drugs on the horizon
A.M. Geretti |
| 12.30 - 12.45 |
The road towards HCV elimination: is the WHO target achievable in time?
M. Puoti |
| 12.45 - 13.00 |
What's new on HIV & CMV coinfection?
M. Lichtner |
| 13.00 - 13.15 | Discussion on Symposium issues |
Sponsored Symposium
Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF
Simposio promozionale di:
Sponsored Symposium
Long Term Treatment Success for PLWH: from clinical trials to real world experience with B/F/TAF
Despite all the advances in therapeutic strategies, HIV remains a complex disease that has a significant impact on the lives of PLWH. To address this complexity, Gilead emphasizes the importance of Long-Term Treatment Success (LTTS). The LTTS has the patient's long-term therapeutic success as its objective. This is achieved not only with the classic parameters of effectiveness and safety but also with a whole series of other aspects that impact the quality of life of the patient living with HIV. Long Term Treatment Success should be the goal for every clinician when facing PLWH. Every person living with HIV must be able to live their lives in the best possible way. The Symposium will analyze how B/F/TAF ensures Long Term Treatment Success both through 5-year follow-up data from clinical trials and with numerous Real World Evidence data from various Italian centers that will be discussed in a roundtable.
Chair: A. Castagna
| 14.30 - 14.45 |
Long term treatment success in the clinical trials: 5 years data with B/F/TAF
S. Lo Caputo |
| 14.45 - 15.25 |
Experiences from Italian cohorts: Round Table Conductor: G. Madeddu Discussants: S. Cicalini, G. d’Ettorre, V. Esposito, L. Gazzola, N. Gianotti |
| 15.25 - 15.30 | Discussion on Symposium issues |
Symposium
At the edge of PREP
Symposium
At the edge of PREP
The efficacy of PREP as an HIV prevention tool is universally recognized. However, most literature data demonstrating PREP efficacy and effectiveness come from studies on MSM. Some aspects of PREP still need to be defined in order to understand its effectiveness and maximize its implementation. In this symposium we want to explore some aspects that still represent gray areas with regard to PREP, in particular the effectiveness and efficacy in populations less represented in clinical trials, such as women, transgender population, IVDU population, etc., with an eye both to real world experiences in these populations and to regulatory aspects of use, or how PREP can fit within protocols of vaccine prevention.
Chairs: D. Calzavara, S. Mattioli
| 15.35 - 15.45 |
Populations not represented in clinical trials: regulatory aspects
W. Nutland |
| 15.45 - 15.55 |
Populations not represented in clinical trials: experiences on the field
M. Appenroth |
| 15.55 - 16.10 |
Ethicality of PREP in vaccine protocols and beyond
G.M. Corbelli |
| 16.10 - 16.25 |
Cost-efficacy of PREP
E. Girardi |
| 16.25 - 16.35 | Discussion on Symposium issues |
Symposium
Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates
Symposium
Monoclonal antibodies and antiviral agents in COVID-19: rational for use and best candidates
The development of therapeutic monoclonal antibodies and direct antiviral agents is currently at the front line of fighting against the COVID-19 pandemic. However, the emergence of SARS-CoV-2 variants, as BA.1 and BA.2 lineages, inducing escape from most of monoclonal antibodies represents a great challenge. Furthermore, as additional variants of concern will likely continue to emerge, there is a high unmet medical need for therapeutics that, alone or in combination, can remain effective as the virus evolves. The Symposium will present the state of the art of virological, clinical and immunological research against COVID-19 with a look at the promising clinical data emerging from the use of monoclonal antibodies and the most recent clinical experiences in the field.
Chairs: A. Antinori, M. Zazzi
| 16.40 - 16.55 |
Neutralizing antibodies overcome SARS-CoV-2 BA.1 and BA.2 antigenic shift
D. Corti |
| 16.55 - 17.10 |
Evolving clinical use and real-life strategies for early treatment of not-hospitalized COVID-19 patients
V. Mazzotta |
| 17.10 - 17.25 |
Could monoclonal antibodies early exposure antagonize anomalies of innate and adaptive immune reponse in COVID-19?
A. Bandera |
| 17.25 - 17.40 | Discussion on Symposium issues |
Symposium
Challenges in HIV cure: getting to zero reservoir
Symposium
Challenges in HIV cure: getting to zero reservoir
Despite sustained control of HIV replication is now achievable with convenient and well-tolerated antiretroviral treatments, the establishment of a lifelong persistent cellular reservoir precludes the eradication of the infection. Thus, characterizing and quantifying the intact viral reservoir is considered an essential prerequisite for the development and the clinical evaluation of curative strategies. Moreover, viral persistence has been demonstrated in several organs and tissues with the highest amount in lymph nodes, gastrointestinal tract, and central nervous system. Understanding the dynamics of drug penetration in the different cellular reservoirs is vital for increasing the efficacy of both antiretroviral therapy and investigational curative approaches. This symposium aims to show and discuss the recent results and advances in laboratory techniques and pharmacology that might lead to pave the way for the eradication of HIV infection.
Chairs: F. Ceccherini - Silberstein, M. Clementi
| 17.45 - 18.00 |
Characterizing and quantifying the HIV reservoir
F.R. Simonetti |
| 18.00 - 18.15 |
Pharmacology of the HIV reservoir
A. Calcagno |
| 18.15 - 18.45 |
Round table Discussants: A. Calcagno, A. De Maria, G. Nunnari, F. Simonetti, O. Turriziani |
Oral Communications
PrEP: new data and issues
Oral Communications
PrEP: new data and issues
Chairs: M.G. Di Benedetto, P. Meli
| 10.05 - 10.15 |
OC 1 Impact of SIMIT PrEP eligibility criteria on retention in care and new sexually transmitted infections acquisition
|
| 10.17 - 10.27 |
OC 2 Sexually transmitted infection and adherence in an Italian access program of HIV pre-exposure prophylaxis (ItaPrEP)
|
| 10.29 - 10.39 |
OC 3 Prevalence of anal HPV infection among PrEP users screened through a self-administered Point-of-Care test: data from a community-based PrEP programme in Milan
|
| 10.41 - 10.51 |
OC 4 PrEP use disclosure to sexual partners, friends and relatives: a psycho-social analysis
|
Oral Communications
Immunological efficacy of SARS-CoV-2 vaccine I
Oral Communications
Immunological efficacy of SARS-CoV-2 vaccine I
Chairs: A. Bandera, F. Castelli
| 11.10 - 11.20 |
OC 5 Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count
|
| 11.22 - 11.32 |
OC 6 Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count
|
| 11.34 - 11.44 |
OC 7 Longitudinal characterization of interferon and antibody response following vaccination against SARS-CoV-2 in patients with HIV-1 infection
|
| 11.46 - 11.56 |
OC 8 T-cell and humoral responses to mRNA-1273 vaccine up to 6 months in late presenter people living with HIV (PLWH)
|
Expert Meeting
Narrative Medicine applied to Vaccination during Covid-19 pandemic
Con il supporto di:
Expert Meeting
Narrative Medicine applied to Vaccination during Covid-19 pandemic
Considering SARS-CoV-2 rapid spread and mortality rate, effective vaccines are needed to control the pandemic. Population is called to make a choice: to accept or refuse vaccination. Data of vaccination clinical trials have shown good results both in efficacy and safety, however long-term data are still to come; meanwhile the virus mutates, and the polarization between the Pro Vax and the No Vax groups, with a number in between identified as the Hesitancy group, is growing, despite the majority of people are Pro Vax. The aim of the Expert Meeting is to debate on different perceptions of people around vaccines and understand propensity to remain vaccinated against infectious diseases, taking advantage of the results of a research based on Narrative Medicine applied to COVID-19 vaccination.
Moderator: S. Vella
Discussants: M.G. Marini, F. Moccia, E. Volpato
Special Session
How to use U=U to fight stigma
Special Session
How to use U=U to fight stigma
Undetectable=Untransmittable (U=U) concept represents a revolution for people living with HIV. It means the end of fear of transmitting the infection, even through unprotected sex. The end of stigma. In Italy, the Consensus Conference (published by sections L and M of Ministry of Health's CTS - Technical Scientifical Committee) formulated U=U concept in an extensive, clear, doubt free approach. This evidence has neither been acquired by many doctors, nor explained to many people living with HIV. There is no communication campaign directed to the general population. In this session we share different experiences, showing how U=U positively improved the social life of people living with HIV, and how on the other hand the absence of adequate information directed to the general population and institutions, contributes to maintain heavy stigma against HIV.
Chairs: G.V. Calvino, A. Moznich
Oral Communications
COVID-19: clinical management
Oral Communications
COVID-19: clinical management
Chairs: M. Bassetti, R. Cauda
| 14.30 - 14.40 |
OC 13 Home prescription treatment and mortality risk after hospitalization with symptomatic COVID- 19 disease
|
| 14.42 - 14.52 |
OC 14 In vivo efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages
|
| 14.54 - 15.04 |
OC 15 Anemia is strongly associated with severity and mortality of COVID-19 in hospitalized patients
|
| 15.06 - 15.16 |
OC 16 Clinical characteristics and outcomes of COVID-19 in vaccinated versus not-vaccinated hospitalized patients: data from an Italian reference hospital
|
Oral Communications
Pathogenesis & Immunology
Oral Communications
Pathogenesis & Immunology
Chairs: C. Agrati, G.C. Marchetti
| 15.35 - 15.45 |
OC 17 Impact of SARS-CoV-2 infection in a relevant three-dimensional human bronchial cell culture model of Cystic Fibrosis
|
| 15.47 - 15.57 |
OC 18 Oral immunity characterization in saliva from asymptomatic and severe COVID19 patients
|
| 15.59 - 16.09 |
OC 19 Therapeutic monoclonal antibody treatment restores immune homeostasis and did not prevent the expansion of anti-SARS-CoV-2 adaptive immune response in mild/moderate COVID-19 patients
|
| 16.11 - 16.21 |
OC 20 Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the early phases of chronic infection even in the setting of limited liver damage
|
Oral Communications
From HIV to SARS-CoV-2
Oral Communications
From HIV to SARS-CoV-2
Chairs: A. Callegaro, F. Maggi
| 16.40 - 16.50 |
OC 21 Intact proviral DNA and chromosome integration sites in peripheral blood lympho-monocytes of early treated acute HIV infections
|
| 16.52 - 17.02 |
OC 22 Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change in Patients Treated During Primary HIV Infection: Results from the INACTION P25 Study
|
| 17.04 - 17.14 |
OC 23 Efficacy, tolerability and pharmacokinetics of doravirine in the clinical setting
|
| 17.16 - 17.26 |
OC 24 Are Minions useful in the lab workflow? Comparison between long and short sequencing in COVID-19 surveillance
|
| 17.28 - 17.38 |
OC 25 In vitro activity of molnupiravir in combination with GC-376 or PF-07321332 against SARS-CoV-2
|
Oral Communications
Metabolic alterations: effect of drugs and diseases
Oral Communications
Metabolic alterations: effect of drugs and diseases
Chairs: S. Di Giambenedetto, L.A.R. Rancilio
| 17.45 - 17.55 |
OC 26 From NAFLD to MAFLD: implications of change in terminology in PWH
|
| 17.57 - 18.07 |
OC 27 The pathway of NAFLD vs MAFLD toward significant fibrosis
|
| 18.09 - 18.19 |
OC 28 With or Without TAF? What is the difference? Data from a real-life setting
|
| 18.21 - 18.31 |
OC 29 Impact of COVID-19 pandemic on incidence and prevalence of metabolic syndrome in PLWH
|
Satellite Symposium
Hepatitis Delta in HIV/HBV Infected Patients
Con la sponsorizzazione non condizionante di:
Satellite Symposium
Hepatitis Delta in HIV/HBV Infected Patients
Viral liver diseases are frequent comorbidities and major contributors to death in HIV-positive individuals on antiretroviral therapy. Due to similarities in transmission routes, persons living with HIV (PLWH) are at risk for HDV infection. The lack of satisfactory treatment for hepatitis delta virus (HDV) infection has meant a major threat for developing cirrhosis and liver cancer in this population. Recent data gathered from HIV ICONA Cohort suggest that HDV infection among PLWH is underdiagnosed, although HDV entails a high risk of liver disease progression. Because effective drugs to treat HDV are now available, it is even more crucial increase awareness to identify patients at an early stage of liver disease. During the Symposium we will provide an exceptional overview of HDV disease among PLWD, from its diagnosis to its management, sharing the most up to date evidences of HDV treatment.
Chair: M. Puoti
| 10.05 - 10.10 | Introduction |
| 10.10 - 10.30 |
Epidemiological characteristics of HDV infection in HIV patients - the ICONA Cohort
A. d'Arminio Monforte |
| 10.30 - 10.50 |
Managing Viral Hepatitis D and new treatment option for HDV
P. Lampertico |
| 10.50 - 11.05 | Discussion on Symposium issues |
Oral Poster
COVID-19: treatment strategies II
Oral Poster
COVID-19: treatment strategies II
Chairs: V. Cento, L. Sasset
| 11.10 - 11.15 |
OP 7 Use of Sotrovimab in a cohort of Pregnant Women with a high risk of COVID 19 progression: a single-center experience
|
| 11.17 - 11.22 |
OP 8 Remdesivir does not influence SARS-CoV-2 RNA viral load kinetics in nasopharyngeal swab specimens of COVID-19 hospitalized patients: a real-life experience
|
| 11.24 - 11.29 |
OP 9 Anti-spike monoclonal antibodies to prevent hospitalization in mild COVID-19: preliminary data of an ongoing large observational multicenter study (CONDIVIDIAMO)
|
| 11.31 - 11.36 |
OP 10 Early Use of Short-Course Remdesivir and Monoclonal Antibodies May Reduce The Risk of Disease Progression in Hospitalized Patients With COVID-19: a Single Center Retrospective Study
|
| 11.38 - 11.43 |
OP 11 Continuous Positive Airway Pressure in SARS-CoV-2 associated Acute Respiratory Distress Syndrome: timing to maximize results
|
| 11.45 - 11.50 |
OP 12 EpCOT: an open-label, controlled, randomized clinical trial on the efficacy of early prone-positioning in patients with mild pneumonia due to SARS-CoV-2
|
Sponsored Symposium
Cabotegravir + rilpivirine long-acting: are we ready for the new era?
Con il supporto di:
Sponsored Symposium
Cabotegravir + rilpivirine long-acting: are we ready for the new era?
Advances in the efficacy of antiretroviral therapy led to a shift in treatment focus to emphasize convenience, tolerability, and overall acceptability of HIV therapy. This has culminated in the development of efficacious single-tablet daily oral regimens, which offer simplicity and convenience. Despite this, the need for life-long daily pill-taking can present substantial challenges that can be broadly grouped into three categories: adherence issues, emotional issues (including stigmatization concerns and the daily reminder of HIV status) and medical issues, such as difficulty swallowing, drug-food and drug-drug interactions, and pill burden. Innovations and treatment options that can fill the unmet needs of people living with HIV, such as long-acting non-oral regimens, could support patients to overcome treatment barriers and improve their quality of life. Objective of this symposium is to discuss the clinical trials data about Cabotegravir + Rilpivirine long-acting regimen, both in terms of efficacy and safety as well as Patient Reported Outcomes and treatment preference reported by patients.
Chairs: S. Bonora, G. Rizzardini
| 12.15 - 12.35 |
Cabotegravir + rilpivirine long-acting therapy: what the data tells us
S. Nozza |
| 12.35 - 12.55 |
Patient reporting outcomes and treatment preferences
A. Cingolani |
| 12.55 - 13.15 | Questions & Answers |
Oral Communications
Metabolic issues in effective HAART
Oral Communications
Metabolic issues in effective HAART
Chairs: E. Focà , N. Frattini
| 13.15 - 13.25 |
OC 9 Role of Emtricitabile/Tenofovir Alafenamide/Bictegravir on metabolic and hepatic safety: data from Surveillance Cohort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) project
|
| 13.27 - 13.37 |
OC 10 Machine learning algorithm to predict weight change in ART experienced PWH
|
| 13.39 - 13.49 |
OC 11 In vitro model of adypocite differentiation under TAF, TDF and INSTIs selective challenge
|
| 13.51 - 14.01 |
OC 12 Liver enzymes levels, metabolic and renal profile modifications after switching from TDF to TAF- based regimens among ART experienced PLWH in ICONA cohort
|
Expert Meeting
The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations
Con il supporto di: 
Expert Meeting
The new recombinant adjuvanted vaccine against Herpes Zoster: clinical data and recommendations
There is a substantial unmet medical need associated with herpes zoster (HZ) and its complications, particularly in older adults and those who are immunocompromised (IC). Current disease management of HZ is not optimal. Early treatment with antiviral drugs, initiated within 72 hours of rash onset, decreases the incidence of new lesion formation, accelerates healing and the resolution of acute pain. Populations at increased risk for developing HZ are those having a decline in immune function, including older adults or individuals who are IC. Individuals who are IC due to haematological malignancies (HM) and solid tumours, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), treatments such as chemo- or radiotherapy, haematopoietic stem cell transplantation (HSCT), immune suppression following organ transplantation or therapy with high doses of corticosteroids are also at increased risk of developing HZ. Individuals who are IC also have an increased risk of disseminated disease. The Recombinant Zoster Vaccine (RZV) is available in Italy since 2021. RZV has been shown to be highly effective at preventing shingles and post-herpetic neuralgia in adults older than 50 years. The vaccine is also effective at protecting adults older than 18 years who are at increased risk of herpes zoster. In the Recommendations of the Italian society for infectious and tropical diseases (SIMIT) for adult vaccinations document, published in 2021, SIMIT recommended RZV for the prevention of HZ and PHN in older adults (>65 yo) and for several categories of at higher risk subjects including HIV+ patients.
Chair: C.M. Mastroianni
| 14.30 - 14.45 |
Scientific and clinical profile of the new recombinant adjuvanted vaccine against HZ
G. Gabutti |
| 14.45 - 15.00 |
The prevention of HZ in at higher risk subjects: the Recommendations of the Italian Society for Infectious and Tropical Diseases (SIMIT)
M. Andreoni |
| 15.00 - 15.15 |
Vaccination against HZ directly offered in the Infectious Diseases center: the «Milan» experience
G. Rizzardini |
| 15.15 - 15.30 | Discussion on Expert Meeting issues |
Interactive Expert Meeting
Affairs of the heart in HIV: redundant or a key challenge?
Con la sponsorizzazione non condizionante di:
Interactive Expert Meeting
Affairs of the heart in HIV: redundant or a key challenge?
PLWH may be predisposed to higher risk of Cardiometabolic Disorders such as dyslipidemia, cardiovascular disease and diabetes. In fact, metabolic syndrome affects up to 52% of PLWH. In this interactive round table, innovative individualized treatment strategies for the management of PLWH at risk or with cardiometabolic disorders will be discussed.
Moderator: G. Di Perri
Discussants: A.M. Cattelan, R. Gagliardini, C. Gervasoni, A. Saracino
Expert Meeting
Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies
Expert Meeting
Evolving models of care in the management of Gram+ infectious diseases: the role of long-acting antibiotic therapies
The increase of multidrug resistance among Gram-positive pathogens, particularly among staphylococci and enterococci, represents a major health care problem, since it results in significant morbidity, mortality, and health care costs. The emergence of such resistant bacterial strains highlights the need to optimize treatment approaches. In this view, novel lipoglycopeptides endowed with long-term activity allowing single-shot administration would be extremely useful and may represent an attractive therapeutic option alternative for early hospital discharge, a cost-saving and a resource-saving approach. Furthermore, long-term intravenous antibiotic therapy poses a particular challenge, specially in this ongoing pandemic situation, for treating patients classified as vulnerable or at highrisk for complications, such as PWID (persons who inject drugs) or those lacking social support, including frail elderly and/or those who are homeless or with an underlying psychiatric illness. This approach may offer improved quality of life for patients, considering benefits, such as no need for a central line for daily infusions, fast hospital discharge, and less need for laboratory monitoring.
Chairs: F. De Iaco, C.M. Mastroianni
| 16.40 - 16.45 |
Introduction
C.M. Mastroianni |
| 16.45 - 17.05 |
Bacterial Infections in difficult-to-treat patients
A.M. Cattelan |
| 17.05 - 17.25 |
Interaction between emergency medicine and infectious disease
V. Cianci |
| 17.25 - 17.35 |
Questions & Answers
F. De Iaco, C.M. Mastroianni |
| 17.35 - 17.40 |
Final considerations and take-home messages
F. De Iaco |
Oral Communications
Special issues in clinical HIV
Oral Communications
Special issues in clinical HIV
Chairs: G. Parruti, B. Suligoi
| 17.45 - 17.55 |
OC 30 Final immunovirological data from the p25- Italian Network of Acute HIV Infection (INACTION) cohort
|
| 17.57 - 18.07 |
OC 31 Effect of 12-week cART on gut mucosal immunity and microbiome in PHI
|
| 18.09 - 18.19 |
OC 32 PLWH with advanced HIV disease are at higher risk for becoming difficult to treat: data from a large cohort of PLWH starting modern ART regimens
|
| 18.21 - 18.31 |
OC 33 Weight change in obese and overweight PWH: the impact of SARS-CoV-2 pandemic
|
Oral Poster
Treatment of naive PLWH: current strategies and rapid start of ART
Oral Poster
Treatment of naive PLWH: current strategies and rapid start of ART
Chairs: M.E. Quiros Roldan, L. Sighinolfi
| 11.10 - 11.15 |
OP 13 Reasons for choosing DRV/cob/FTC/TAF in ART-naïve and ART-experienced patients: data from the Icona Cohort
|
| 11.17 - 11.22 |
OP 14 Blood telomere length in treatment-naive HIV-infected adults starting dolutegravir plus lamivudine versus triple regimen with two nucleosides
|
| 11.24 - 11.29 |
OP 15 BIC/FTC/TAF in ART-naïve key populations: real-life data from the Icona cohort
|
| 11.31 - 11.36 |
OP 16 A pilot study of the impact of a rapid ART initiation in advanced HIV disease
|
| 11.38 - 11.43 |
OP 17 Rapid ART initiation in a single-center italian cohort: an observational analysis
|
| 11.45 - 11.50 |
OP 18 Viro-immunological effectiveness of different integrase strand-transfer inhibitor-based antiretroviral therapy regimens. A single center retrospective study
|
Oral Poster
Predictors of COVID-19 severity
Oral Poster
Predictors of COVID-19 severity
Chairs: G. Lapadula, P. Nasta
| 13.25 - 13.30 |
OP 31 Hospitalization for COVID-19 or with SARS-CoV-2 infection during two different epidemic periods in Milan, Italy: data from Luigi Sacco Hospital registry
|
| 13.32 - 13.37 |
OP 32 Prognostic value of transaminases and bilirubin levels at admission to hospital on disease progression and mortality in patients with COVID-19 - an observational retrospective study
|
| 13.39 - 13.44 |
OP 33 Early predictors of clinical deterioration in a cohort of outpatients with COVID-19 in Southern Italy: a multicenter observational study
|
| 13.46 - 13.51 |
OP 34 Risk factors for in-hospital mortality in COVID-19 patients with end stage renal diseases requiring manteinance hemodialysis
|
| 13.53 - 13.58 |
OP 35 Clinical characteristics and outcomes of COVID-19 hospitalized patients in the current pandemic phase
|
| 14.00 - 14.05 |
OP 36 Laboratory and clinical biomarkers helps to predict severity of CT score in COVID19 patients: an observational study
|
Oral Poster
Viro-immunological correlates of COVID-19 severity
Oral Poster
Viro-immunological correlates of COVID-19 severity
Chairs: I. Bon, I. Vicenti
| 14.30 - 14.35 |
OP 43 PTX3 is a strong predictor of death among patients with COVID-19
|
| 14.37 - 14.42 |
OP 44 The role of antigen load on viral clearance and severity in SARS-CoV-2 infection
|
| 14.44 - 14.49 |
OP 45 Dysregulation in IFN-omega levels and anti-IFN-omega neutralizing antibodies correlate with biochemical and hematological parameters predictive of disease severity in COVID-19 male patients
|
| 14.51 - 14.56 |
OP 46 Characterization of IFN response in PBMC from children and adolescent after SARS-CoV-2 infection
|
| 14.58 - 15.03 |
OP 47 Immunological profiles of SARS-CoV-2 infection: the link between cytokine storm, clinical severity and post-COVID syndrome
|
| 15.05 - 15.10 |
OP 48 Respiratory and peripheral IFN response and frequency of T cell activation in COVID-19 patients
|
Oral Poster
Neuropsychological complications in COVID-19
Oral Poster
Neuropsychological complications in COVID-19
Chairs: T.S. Prestileo, V. Spagnuolo
| 15.35 - 15.40 |
OP 55 Dementia and COVID-19 outcomes: findings from a multicentric study in Campania region
|
| 15.42 - 15.47 |
OP 56 COVID-19 neurocognitive impairment (COVID-19-NCI): an attempt for definition and clinical assessment
|
| 15.49 - 15.54 |
OP 57 Neuropsychological performance (NP) following COVID-19: prevalence and predictors
|
| 15.56 - 16.01 |
OP 58 Is plasma neurofilament light chain measurement relevant in long-COVID?
|
| 16.03 - 16.08 |
OP 59 SARS-CoV-2 hampers Dopamine production in iPS-derived dopaminergic neurons
|
| 16.10 - 16.15 |
OP 60 Early phase approach in SARS CoV-2 infection: a single center one-year real life experience
|
Oral Poster
Cardiovascular diseases, osteoporosis but not only
Oral Poster
Cardiovascular diseases, osteoporosis but not only
Chairs: L. Calza, G. Mazzola
| 16.40 - 16.45 |
OP 67 Weight gain in people living with HIV under antiretroviral therapy: do our strategies make a difference?
|
| 16.47 - 16.52 |
OP 68 PLWH (People Living With HIV): a single centre retrospective observational study on cardiovascular risk factors
|
| 16.54 - 16.59 |
OP 69 Relationship between vitamin D deficiency and cardiovascular disease in virologically suppressed HIV-1-infected patients
|
| 17.01 - 17.06 |
OP 70 Effect of bisphosphonates on vertebral fractures in HIV infected males: a 7-years study
|
| 17.08 - 17.13 |
OP 71 Association between Health Literacy, care engagement and assessment of risk behaviours in an Italian cohort of people living with HIV
|
| 17.15 - 17.20 |
OP 72 Mental health assessment in people living with HIV/AIDS (PLWHA): preliminary data from a referral HIV center
|
Oral Poster
Measuring HIV stigma and disclosure
Oral Poster
Measuring HIV stigma and disclosure
Chairs: B.M. Celesia, T. Di Giovanni
| 17.45 - 17.50 |
OP 78 Tackling the misunderstanding and stigma of HIV: a survey on 1007 Italian citizens
|
| 17.52 - 17.57 |
OP 79 HIV-related stigma among Italian adults: results of an online survey
|
| 17.59 - 18.04 |
OP 80 Determinants of non disclosure of HIV status in PLWHIV to other than health care workers
|
| 18.06 - 18.11 |
OP 81 Knowledge and impact of U=U among PLHIV, healthcare professionals and the general population in Italy: a qualitative study
|
| 18.13 - 18.18 |
OP 82 Do people living with HIV have a better knowledge of HIV and STIs compared to people without HIV? A survey study in Sardinia, Italy
|
| 18.20 - 18.25 |
OP 83 Impact of HIV-related stigma on social support, mental health and quality of life in an Italian cohort of people living with HIV
|
Oral Poster
COVID-19: treatment strategies I
Oral Poster
COVID-19: treatment strategies I
Chairs: C. Alteri, G. Cenderello
| 10.05 - 10.10 |
OP 1 Real-life data on early treatment with antivirals in outpatients with mild COVID-19 symptoms
|
| 10.12 - 10.17 |
OP 2 Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 and delta sub-lineage AY.4.2
|
| 10.19 - 10.24 |
OP 3 Sarilumab plus standard of care versus standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE Study)
|
| 10.26 - 10.31 |
OP 4 Safety and efficacy of antiviral agents in SARS-CoV-2 infected patients: a real-life experience
|
| 10.33 - 10.38 |
OP 5 Efficacy of Early Antiviral Therapies among High-Risk Patients with Mild to Moderate COVID-19
|
| 10.40 - 10.45 |
OP 6 Real life experience on the use of anti-SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression among inpatients and outpatients: a monocentric experience
|
Oral Poster
PrEP: real life experience
Oral Poster
PrEP: real life experience
Chairs: F. Leserri, M. Marra
| 11.10 - 11.15 |
OP 19 PrEP in Italy: how many people access it and what kind of services are offered?
|
| 11.17 - 11.22 |
OP 20 HIV Pre-Exposure Prophylaxis (PrEP): the experience of the outpatient clinic of Perugia
|
| 11.24 - 11.29 |
OP 21 Impact of a pre-exposure prophylaxis program on HIV and other sexually transmitted infections over the last three years in a third level hospital: the experience from Padua
|
| 11.31 - 11.36 |
OP 22 Pre-Exposure Prophylaxis (PrEP) Service in Bergamo: three-year experience
|
| 11.38 - 11.43 |
OP 23 HIV Pre-exposure Prophylaxis in a Large Teaching Hospital in Milan: the CSL-PrEP Cohort experience
|
| 11.45 - 11.50 |
OP 24 The Italian experience of Pre-Exposure Prophylaxis (PrEP) users and serum creatinine variation: a two centers retrospective analysis
|
Oral Poster
Access to test and educational aspects
Oral Poster
Access to test and educational aspects
Chairs: A. Bianchi, G. D'Offizi
| 12.15 - 12.20 |
OP 25 HIV testing in community-based centers and MSM premises: different settings, same needs
|
| 12.22 - 12.27 |
OP 26 HIV testing: are we missing some opportunities?
|
| 12.29 - 12.34 |
OP 27 Population of the Bergamo Check-Point. A first analysis of Cobatest data
|
| 12.36 - 12.41 |
OP 28 Veneto Region “RECALL” project to discover HCV+people: the experience of the “Osservatorio Infettivologico“ in Verona
|
| 12.43 - 12.48 |
OP 29 Prejudice and perceived HIV risk among High School Students
|
| 12.50 - 12.55 |
OP 30 Pilot experience of comprehensive sexuality education among Italian adolescents: preliminary results from the EduForIST project, April 2022
|
Oral Poster
HCV eradication: general and key populations
Oral Poster
HCV eradication: general and key populations
Chairs: P. Colletti, M. Cusini
| 13.25 - 13.30 |
OP 37 Long-term outcomes in GT3 HCV/HIV co-infected subjects treated with DAAs: impact on metabolic profile
|
| 13.32 - 13.37 |
OP 38 Chronic Hepatitis C cascade of care in Prisoners. Is there still some work to be done? Analysis of two penitentiaries in northern Italy
|
| 13.39 - 13.44 |
OP 39 HCV point of care screening in people tested for SARS-CoV-2 in a social-housing neighbourhood of Milan, Italy
|
| 13.46 - 13.51 |
OP 40 Hepatitis C virus (HCV) micro-elimination in the hospital setting: the results of the HCV Caserta hospital project
|
| 13.53 - 13.58 |
OP 41 Patients’ reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care and treatment
|
| 14.00 - 14.05 |
OP 42 Characterisation of viral infections in a cohort of migrants living in southern italy
|
Oral Poster
Issues on mental health, sexual health and STIs
Oral Poster
Issues on mental health, sexual health and STIs
Chairs: R. Galipò, D. Ripamonti
| 14.30 - 14.35 |
OP 49 Predictors of mental and sexual health after COVID-19 Pandemic in a group of MSM living with HIV
|
| 14.37 - 14.42 |
OP 50 Single nucleotide polymorphisms affecting neuroinflammation biomarkers in different clinical groups of HIV-affected patients
|
| 14.44 - 14.49 |
OP 51 Treatment response in syphilis reinfection among People living with HIV: high baseline titer and delayed assessment affects the risk of serological-non-response
|
| 14.51 - 14.56 |
OP 52 Increasing incidence of Mycoplasma genitalium infection in PLWHIV and PrEP users
|
| 14.58 - 15.03 |
OP 53 Alteration of IFN pathways in anal cells from HIV-1/HPV co-infected men
|
| 15.05 - 15.10 |
OP 54 Efficacy of late HPV vaccination in young HIV+ MSM
|
Oral Poster
New issues on dual therapy
Oral Poster
New issues on dual therapy
Chairs: M. De Gennaro, D. Losito
| 15.35 - 15.40 |
OP 61 Efficacy and Durability of Dual Antiretroviral Regimens as switch therapy in treatment-experienced People Living with HIV (PLWH): data from the ARCA cohort
|
| 15.42 - 15.47 |
OP 62 Characterization of virologically suppressed HIV infected individuals potential eligible to the long-acting combination of cabotegravir plus riplivirine: results from the Italian ARCA cohort
|
| 15.49 - 15.54 |
OP 63 Long acting cabotegravir plus rilpivirine compassionate use program: a narrative description of the Italian experience
|
| 15.56 - 16.01 |
OP 64 Immunological recovery in PLWHIV starting dolutegravir plus lamivudine as first-line regimen: data from the ODOACRE cohort
|
| 16.03 - 16.08 |
OP 65 Comparison of efficacy and tolerability of Dolutegravir / Rilpivirine and Dolutegravir / Lamivudine in experienced HIV-1 positive patients switched from a three-drug regimen based on Non-Nucleoside Reverse Transcriptase Inhibitors: a multicenter cohort study in Italy
|
| 16.10 - 16.15 |
OP 66 Comparing the efficacy and tolerability of dolutegravir plus rilpivirine versus dolutegravir plus lamivudine in a multicenter cohort
|
Oral Poster
Vulnerable and key population: local experiences
Oral Poster
Vulnerable and key population: local experiences
Chairs: E. Girardi, A. Moznich
| 16.40 - 16.45 |
OP 73 Community-Based Centers (CBCs): sexual health needs and prevention knowledge among MSM in Lazio
|
| 16.47 - 16.52 |
OP 74 Injecting drug use, irrespective of harm reduction measures, is strongly associated with HCV infection: results of a structured questionnaire administered during HCV screening sessions in low threshold harm reduction services
|
| 16.54 - 16.59 |
OP 75 High prevalence of HCV infection among people screened in unconventional low threshold settings: results of an outreach program of screening and linkage to care for people using drugs
|
| 17.01 - 17.06 |
OP 76 Descriptive analysis and retention in care of a cohort of HIV-positive migrants (AMIGO: A HIV-positive MIGrants cohort at AOU Careggi)
|
| 17.08 - 17.13 |
OP 77 A qualitative survey on facilitating factors and barriers to access and continuum of care: point of view of HIV-positive transgender migrant women living in Florence
|
Oral Poster
Models of COVID-19 pathogenesis and response to vaccination
Oral Poster
Models of COVID-19 pathogenesis and response to vaccination
Chairs: A. Riva, C. Tincati
| 17.45 - 17.50 |
OP 84 Human iPSC-derived motor neurons are productively infected by SARS-CoV-2
|
| 17.52 - 17.57 |
OP 85 SARS-CoV-2 infection of airway epithelium triggers endothelial cells activation
|
| 17.59 - 18.04 |
OP 86 Specific CD4+ and CD8+ T cell response of SARS-CoV-2 S epitopes using tetramers & monocyte dysregulation in fully vaccinated donors and recovered patients
|
| 18.06 - 18.11 |
OP 87 Immune responses after three doses of BNT162b2 mRNA vaccine in a cohort of HIV-vertically transmitted patients
|
| 18.13 - 18.18 |
OP 88 Comparison between QuantiFERON SARS-CoV 2 kit and Activation Induced Cell Markers (AIMs) assay in 21 non-vaccinated patients with late COVID19 infection
|
| 18.20 - 18.25 |
OP 89 An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein
|
09:00 - 10:00
Keynote Lectures
10:05 - 11:05 | Symposium
Comorbidities of contemporary relevance
11:10 - 12:10 | Sponsored Symposium
Remdesivir: key-role in COVID-19 management
12:15 - 13:15 | Symposium
A practical approach to HIV patients' management
13:15 - 14:15 | Symposium
Immunological control over HIV : from models of spontaneous control to immunotherapeutic approaches
14:15 - 15:15 | Symposium
COVID-19 from early treatment to long-term care
15:20 - 16:20 | Symposium
Update on antiretroviral therapy: answers and suggestions during a pandemic era
16:25 - 16:45
ICAR 2022 Special Awards and Closing Remarks
10:05 - 11:05 | Expert Meeting
Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?
11:10 - 12:10 | Oral Communications
Resistance to antiretroviral
12:15 - 13:15 | Oral Communications
HIV and SARS-CoV-2: two intersecting epidemics
13:15 - 14:15 | Oral Communications
Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities
14:15 - 15:15 | Oral Communications
Dual therapy in naive and switched PLWH
15:20 - 16:20 | Oral Communications
Complexities of SARS-CoV-2 infection
10:05 - 12:10 | Symposium
The Italian Fast-Track Cities Network
12:15 - 13:15 | Expert Meeting
Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus
13:15 - 14:15 | Oral Communications
Immunological efficacy of SARS-CoV-2 vaccine II
14:15 - 15:15 | Oral Communications
Mental health and predictors of AIDS and non-AIDS defining co-pathologies
15:20 - 16:20 | Oral Communications
Insights on epidemiological and clinical management of hepatitis viruses
10:05 - 10:55 | Oral Poster
COVID-19: considerations of special populations
11:10 - 12:00 | Oral Poster
HIV and SARS-CoV-2: from in vivo to in vitro
12:15 - 13:05 | Oral Poster
Acute COVID-19 and post COVID-19 syndrome
13:15 - 14:05 | Oral Poster
Open questions about ART efficacy
14:20 - 15:10 | Oral Poster
Prevention and access to services during COVID pandemic
15:20 - 16:10 | Oral Poster
Immunopathogenesis of HIV
10:05 - 10:55 | Oral Poster
Toxicity of antiretroviral therapy
12:15 - 13:05 | Oral Poster
Immunological efficacy of COVID-19 vaccination in vulnerable populations
13:15 - 14:05 | Oral Poster
Immunological complexity in COVID-19
14:20 - 15:10 | Oral Poster
SARS-CoV-2: from in vivo to in vitro
Keynote Lectures
Keynote Lectures
Chairs: M.L. Cosmaro, M. Galli
| 09.00 - 09.30 |
Anti-HIV therapy as a guide to treat COVID-19
C.F. Perno |
| 09.30 - 10.00 |
Comparing the Mental Health Trajectories of PLWH during the pandemic period with the prepandemic situation: impact of geographic differences and different access to health care facilities
F. Lampe |
Symposium
Comorbidities of contemporary relevance
Symposium
Comorbidities of contemporary relevance
In recent years, the comorbidities of HIV infection, initially associated with side effects of ART, have turned into pathological conditions more often related to aging and lifestyles. Among ART side effects, weight gain remains a concern especially in PWH receiving integrase inhibitors, and mechanisms are still unclear. Beyond ART, sexually transmitted infections are among those more clinically relevant in PWH because of their high frequency and transmissibility, despite most can be prevented or treated. In this context, HPV infection is of particular interest because it is implicated in the development of tumors, which remain a relevant cause of mortality in PWH.
Chairs: P. Maggi, B. Marchini
| 10.05 - 10.20 |
Pathogenetic aspects of weight gain under ART
L. Taramasso |
| 10.20 - 10.35 |
Evolving concepts in Sexually Transmitted Infections
G. Villa |
| 10.35 - 10.50 |
HPV infection and its consequences: where we stand now
N. Squillace |
| 10.50 - 11.05 | Discussion on Symposium issues |
Sponsored Symposium
Remdesivir: key-role in COVID-19 management
Simposio promozionale di:
Sponsored Symposium
Remdesivir: key-role in COVID-19 management
Remdesivir, the first antiviral drug authorized in Europe for the treatment of COVID-19, has demonstrated its efficacy in three randomized controlled clinical trials, including the gold-standard ACTT-1 study, and, increasingly, in numerous evidences from the real practice. Recent international real-world retrospective analyses on large data sets and a meta-analysis of the most important real-world publications confirmed that hospitalised COVID-19 patients treated with remdesivir had a statistically significant reduction in mortality and improved survival compared to matched controls. Moreover, the PINETREE phase III study on moderate COVID-19 patients revealed high efficacy of remdesivir in reducing hospitalization or mortality rate compared to placebo, results that granted the new recent EMA indication for high risk moderate patients. This Symposium will be an opportunity to give an overview of the evolving patient profile, to present a scientific update on remdesivir efficacy data and to discuss centres organization to manage the treatment of COVID-19 outpatients. The three talks composing the Symposium will then try to address the most important topics regarding COVID-19 patient management with remdesivir.
Chair: R. Bruno
| 11.10 - 11.15 |
Introduction
R. Bruno |
| 11.15 - 11.30 |
The evolution of the COVID-19 patient profile
P. Viale |
| 11.30 - 11.45 |
Remdesivir in the severe patient: new evidences from the Real World
M. Falcone |
| 11.45 - 12.00 |
Remdesivir in the high risk moderate patient: efficacy profile and patient management
E. Nicastri |
| 12.00 - 12.10 | Discussion on Symposium issues |
Symposium
A practical approach to HIV patients' management
Symposium
A practical approach to HIV patients' management
The objectives of this symposium are to provide both clinical management insights on «late presentation in HIV» identifying the unmet needs of specific vulnerable patients, such as migrants, pregnant women, trans individuals, adolescents, and to increase the level of awareness for the HIV management in these specific populations. The program will also include new immuno-pharmacology concepts that may have a role in the future HIV therapy as well as a lecture on some new therapeutic approaches to tubercolosis that can impact the future management of people with HIV.
Chairs: A. Gori, F. Vichi
| 12.15 - 12.30 |
Management of Late presentation in vulnerable populations - Interactive clinical case
C. Pinnetti |
| 12.30 - 12.45 |
Chasing inflammation: is there a role of the immunomodulant agents in HIV? - Interactive clinical case
G.C. Marchetti |
| 12.45 - 13.00 |
New therapeutic approaches to tuberculosis in people living with HIV
A. Matteelli |
| 13.00 - 13.15 | Discussion on Symposium issues |
Symposium
Immunological control over HIV : from models of spontaneous control to immunotherapeutic approaches
Symposium
Immunological control over HIV : from models of spontaneous control to immunotherapeutic approaches
The symposium is intended to address different aspects of the immune control over HIV. In particular, a comprehensive review of the latest notions on known human and animal models of spontaneous control over HIV will be provided. The interaction of the virus with specific cell subpopulations, and in particular stem cell memory cells, will also be illustrated. The most novel specific immunotherapeutic approaches to overcome HIV infection will also be thoroughly reviewed during the symposium.
Chairs: A. Cossarizza, A. Riva
| 13.15 - 13.30 |
HIV and stem cell memory cells: from pathogenesis to therapeutic approaches
L. Manganaro |
| 13.30 - 13.45 |
Immunotherapy as a tool towards cure interventions
M.S. Clerici |
| 13.45 - 14.00 |
Models of spontaneous control over HIV infection
G. Poli |
| 14.00 - 14.15 | Discussion on Symposium issues |
Symposium
COVID-19 from early treatment to long-term care
Symposium
COVID-19 from early treatment to long-term care
This symposium will offer insights in the early and late management of COVID-19. On one end, we will discuss risk stratification of vulnerable individuals who qualify for early treatment of SARS COV-2 infection. On the other end, we will discuss pathogenesis and care of Post-Acute COVID Syndrome (PACS). A clinical case presentation of a vaccinated individual living with HIV will offer the framework to discuss risk stratification for early treatment of immunologically vulnerable populations, as well as how to assess and manage post-acute COVID Syndrome.
Chairs: G. Rizzardini, M. Rizzi
| 14.15 - 14.30 |
From risk stratification to early treatment. How to keep a patient with SARS-CoV-2 out of hospital?
D. Peppa |
| 14.30 - 14.45 |
From acute to post-acute SARS-CoV-2 disease: can we prevent or reverse PACS?
S.G. Deeks |
| 14.45 - 15.15 |
Panel discussion - Clinical models in managing PACS. Is resilience our goal? Discussants: S. Deeks, G. d’Ettorre, A. M. Geretti, G. Guaraldi, D. Peppa, A. Vergori |
Symposium
Update on antiretroviral therapy: answers and suggestions during a pandemic era
Symposium
Update on antiretroviral therapy: answers and suggestions during a pandemic era
Antiretroviral therapy (TARV) has changed the life expectancy of people living with HIV infection and has drastically improved the quality of life of people we care for. The high efficacy of TARV is still hampered by the impossibility of clearing the viral reservoir. Nevertheless, new drugs for modern needs are flourishing and will reach the clinical arena. These compounds will be instrumental for the rapid start of TARV, even in the context of the COVID-19 pandemic, and in the challenge of treating HTE individuals, a polymorphic situation where novel answers are eagerly awaited.
Chairs: T. Bini, P.M. Cinque
| 15.20 - 15.35 |
New drugs for modern needs: from phase II trials up to now
A. Di Biagio |
| 15.35 - 15.50 |
Rapid start in COVID-19 era: what is needed?
C. Mussini |
| 15.50 - 16.15 |
Clinical case: Novel strategies for HTE people Presenter: D. Canetti Discussants: D. Ripamonti, S. Rusconi |
| 16.15 - 16.20 | Discussion on Symposium issues |
ICAR 2022 Special Awards and Closing Remarks
ICAR 2022 Special Awards and Closing Remarks
Chairs: A. Antinori, M.G.L. Cernuschi, F. Maggiolo, M. Zazzi
| 16.25 - 16.40 | ICAR 2022 Special Awards: |
| -ICAR-CROI Awards | |
| -ICAR Scientific Committee Awards | |
| -SIMIT Awards to Best Oral Communications for young researchers | |
| 16.40 - 16.45 | ICAR 2022 Closing remarks |
Expert Meeting
Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?
Con la sponsorizzazione non condizionante di:
Expert Meeting
Heavily-treatment experienced (HTE) patients: who are they? And how should be managed?
Despite the availability of new classes of antiretroviral (ARV) therapy with improved efficacy, some usually heavily-treatment experienced (HTE) patients eventually experience treatment failure due to various factors including viral resistance, drug toxicity, drug intolerance, and poor adherence. Long-term ARV therapy use could lead to decreased efficacy of multiple classes of ARVs, requiring increasingly tailored regimens, and few, if any, remaining ARV options remaining. Therefore, it is important to consider new ARVs with different mechanism of action in the therapeutic approach of these patients: in this context, the oral attachment inhibitor has demonstrated efficacy in adults with multidrug resistant HIV-1 infection in urgent need of new treatment due to resistance, safety, or tolerability issues with their current regimens.
Moderator: S. Lo Caputo
Discussants: A. Castagna, C.F. Perno
Oral Communications
Resistance to antiretroviral
Oral Communications
Resistance to antiretroviral
Chairs: A. Cascio, M.A. Di Pietro
| 11.10 - 11.20 |
OC 34 Evaluation of integrase resistance and its predictors in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings
|
| 11.22 - 11.32 |
OC 35 Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype
|
| 11.34 - 11.44 |
OC 36 Clinical and virological outcomes of difficult to treat patients in a large cohort of PLWH starting modern ART regimens
|
| 11.46 - 11.56 |
OC 37 Durability of Mega ART in a large cohort of treatment experienced people living with HIV: Data from ARCA database
|
Oral Communications
HIV and SARS-CoV-2: two intersecting epidemics
Oral Communications
HIV and SARS-CoV-2: two intersecting epidemics
Chairs: M. Breveglieri, C. Giaquinto
| 12.15 - 12.25 |
OC 38 The Cascade of HIV Care (CoC) of Milan as compared to Italy: data derived from the COA Registry and the Icona cohort- Milan Fast Track City
|
| 12.27 - 12.37 |
OC 39 Effect of COVID-19 pandemic on the HIV cascade of care at a Provincial level
|
| 12.39 - 12.49 |
OC 40 SARS-CoV-2 infection and vaccination coverage among fragile populations in a Local Health Area of Northern Italy
|
| 12.51 - 13.01 |
OC 41 New diagnosis of HIV among transgender women sex-workers across time: results from a multi-year street-based intervention (2017-2020)
|
Oral Communications
Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities
Oral Communications
Diabetes, cardiovascular diseases and STIs. A wide range of comorbidities
Chairs: T. Bini, G. Orofino
| 13.15 - 13.25 |
OC 42 Incident diabetes in course of antiretroviral therapy
|
| 13.27 - 13.37 |
OC 43 Treatment with integrase inhibitors among antiretroviral naïve patients is not associated with increased risk of diabetes mellitus
|
| 13.39 - 13.49 |
OC 44 Non-Alcoholic to Metabolic Associated Fatty Liver Disease: Cardiovascular Implications of a Change in Terminology in Patients Living With HIV
|
| 13.51 - 14.01 |
OC 45 Syphilis infection and re-infection in PLWH and PrEP users: new insights into epidemic dynamics
|
Oral Communications
Dual therapy in naive and switched PLWH
Oral Communications
Dual therapy in naive and switched PLWH
Chairs: S. Carbonara, B.M. Celesia
| 14.15 - 14.25 |
OC 50 Adherence rates and forgiveness to uncomplete adherence to 3TC/DTG
|
| 14.27 - 14.37 |
OC 51 12-Month immunological changes in patients randomized to switch either to BIC/TAF/FTC or DTG/3TC (DEBATE study)
|
| 14.39 - 14.49 |
OC 52 Switch to doravirine with dolutegravir dual regimen compared to other dual dolutegravir-based regimes in clinical practice: a 96-week analysis
|
| 14.51 - 15.01 |
OC 53 Clinical and virological characteristics of people living with HIV who fail to maintain virological suppression after switching to dolutegravir-based two drug regimens. Results from the prospective observational ARCA cohort
|
Oral Communications
Complexities of SARS-CoV-2 infection
Oral Communications
Complexities of SARS-CoV-2 infection
Chairs: P. Bonfanti, A. Saracino
| 15.20 - 15.30 |
OC 58 Prevalence and epidemiological, clinical and microbiological characteristics of bacterial infections in a large cohort of patients admitted for COVID-19 in Campania: a multicentre cohort study
|
| 15.32 - 15.42 |
OC 59 Evaluation of SARS-CoV-2 reinfection risk during the different COVID-19 variants’ spread
|
| 15.44 - 15.54 |
OC 60 Pre-existent socio-economic status and its role in PASC syndrome: results from the VASCO study (VAriabili Socioeconomiche e COVID-19), on the “Surviving-COVID” Cohort, from Bergamo (Italy)
|
| 15.56 - 16.06 |
OC 61 Depressive Symptoms Among Covid-19 Survived Patients One Year After Hospital Discharge: Prevalence and Factors Associated
|
Symposium
The Italian Fast-Track Cities Network
Con la sponsorizzazione non condizionante di:
Symposium
The Italian Fast-Track Cities Network
The Fast-Track Cities initiative (FTCI) is a global partnership between cities and municipalities around the world and four core partners: the International Association of Providers of AIDS-Care (IAPAC), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the United Nations Human Settlements Programme (UN-Habitat) and the City of Paris. Launched on World AIDS Day 2012, the Network has grown to include more than 330 Cities and municipalities that are committed to attain the UNAIDS 95-95-95 targets by 2030. The aim of the Symposium is to focus on the Italian Fast-Track Cities state of the art as now 12 Italian townships are potentially involved. Even if FTCI is mostly a locally organized micro-program, sharing good practice and ideas may improve the effect of single realities and may lead to common actions able to engrave deeply on the HIV epidemics.
Chairs: A. d'Arminio Monforte, S. Patrucco
| 10.05 - 10.20 |
The Global Network example of good practice
B. Audoin |
| 10.20 - 10.35 |
FTC experience from the municipality point of view
M. Messina |
| 10.35 - 11.10 |
Italian Fast Track Cities calls Ukraine
B. Audoin |
| 11.10 - 11.40 |
Common projects already in place and sharing of Cobatest data
M.L. Cosmaro, P. Meli |
| 11.40 - 12.10 | Future common projects and actions. FTCI delegates |
Expert Meeting
Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus
Con la sponsorizzazione non condizionante di:
Expert Meeting
Redefining management and treatment goals in antiretroviral triple therapy: results of a Delphi Consensus
Modern antiretroviral therapy (ART) offers several treatment options characterized by high efficacy and tolerability, and new strategies with less drug regimens and new drugs are now available for the treatment of HIV infection. As definitive data on the long-term success of these new strategies are lacking, a panel of Experts in the care of HIV infection expressed their consensus on which could be the best strategy to achieve and maintain long-term virological and clinical success for PLWH in course of antiretroviral therapy, using Delphi methodology. The main consensus statements developed will be presented and discussed during this Expert Meeting.
Chair: A. Di Biagio
| 12.15 - 12.30 |
Optimizing the ARV treatment focusing on long-term effectiveness and a person-centred approach: consensus guidance using Delphi process
A. Di Biagio |
| 12.30 - 13.10 |
Round table - Delphi Consensus results: Discussants: M. Borderi, S. Di Giambenedetto, G. Guaraldi, P. Maggi - Clinical efficacy: ART-monitoring strategy - Immunology and Pharmacology - Long-term safety - Quality of life assessment |
| 13.10 - 13.15 |
Final considerations
A. Di Biagio |
Oral Communications
Immunological efficacy of SARS-CoV-2 vaccine II
Oral Communications
Immunological efficacy of SARS-CoV-2 vaccine II
Chairs: L. Butini, S. Parisi
| 13.15 - 13.25 |
OC 46 Monitoring saliva and plasma neutralizing activity induced by the administration of a third BNT162B2 vaccine dose
|
| 13.27 - 13.37 |
OC 47 Lower neutralization level against SARS-CoV-2 Omicron (BA.1) variant than against reference strain after a third dose of mRNA vaccine in PLWH
|
| 13.39 - 13.49 |
OC 48 T-cell responses to SARS-CoV-2 Spike protein after 3 doses of BNT162b2 mRNA vaccination in healthy individuals, cross-recognize Alpha, Delta and Omicron variants of concern
|
| 13.51 - 14.01 |
OC 49 CD4 cell count is critical for specific T cell-mediated response in PLWH before and after third dose of COVID-19 vaccine
|
Oral Communications
Mental health and predictors of AIDS and non-AIDS defining co-pathologies
Oral Communications
Mental health and predictors of AIDS and non-AIDS defining co-pathologies
Chairs: M. Farinella, P. Maggi
| 14.15 - 14.25 |
OC 54 Relation between genetic polymorphisms or variants and cognitive impairment in a group of HIV-infected people
|
| 14.27 - 14.37 |
OC 55 A higher CPE score in PLWH with HAND switched to a less neurotoxic regimen is associated to improved memory test (MARAND-X study)
|
| 14.39 - 14.49 |
OC 56 Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART
|
| 14.51 - 15.01 |
OC 57 Association between HIV-1 DNA and clinical outcome in people living with HIV
|
Oral Communications
Insights on epidemiological and clinical management of hepatitis viruses
Oral Communications
Insights on epidemiological and clinical management of hepatitis viruses
Chairs: N. Coppola, G. Gaiera
| 15.20 - 15.30 |
OC 62 Serum HBsAg and highly-sensitive HBV-DNA quantification can predict HBsAg loss after nucleo(s)tide analogue systematic discontinuation in non-cirrhotic patients with chronic hepatitis B
|
| 15.32 - 15.42 |
OC 63 Hepatitis D virus infection in a large cohort of immigrants in Southern Italy a multicenter, prospective study
|
| 15.44 - 15.54 |
OC 64 Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays
|
| 15.56 - 16.06 |
OC 65 Hepatitis C testing, linkage to care and treatment during COVID-19 era in a north-east Italian hospital: what can we still need to do to improve elimination?
|
Oral Poster
COVID-19: considerations of special populations
Oral Poster
COVID-19: considerations of special populations
Chairs: V. Giacomet, F. Vichi
| 10.05 - 10.10 |
OP 90 Impact of patients’ characteristics and comorbidities on in-hospital mortality during the first three waves of COVID-19 pandemic. Results from the Brescia HUB project
|
| 10.12 - 10.17 |
OP 91 SARS-CoV-2 infection and COVID-19 disease in PLWH
|
| 10.19 - 10.24 |
OP 92 Evolution of SARS-CoV-2 Variants of Concerns (VOC) over a period of Delta and Omicron variants co-circulation: impact on clinical outcomes among patients (pts) hospitalized for COVID-19 in an Italian reference hospital in the first trimester of 2022
|
| 10.26 - 10.31 |
OP 93 New issues in SARS-CoV-2 vaccination response among Health-care workers: slow responders and peri-vaccination infections
|
| 10.33 - 10.38 |
OP 94 Antibody response in women vaccinated against SARS-CoV-2 during pregnancy and respective babies at birth
|
| 10.40 - 10.45 |
OP 95 Predictors of mortality in a cohort of oldest old subjects hospitalized for COVID-19
|
Oral Poster
HIV and SARS-CoV-2: from in vivo to in vitro
Oral Poster
HIV and SARS-CoV-2: from in vivo to in vitro
Chairs: D. Cattaneo, F. Saladini
| 11.10 - 11.15 |
OP 102 Trends of HIV-1 drug resistance and APOBEC editing in PBMC compartment over the last decade
|
| 11.17 - 11.22 |
OP 103 Trend over time of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) and their drivers: cohort study from ARCA
|
| 11.24 - 11.29 |
OP 104 Sotrovimab-emergent resistance in immunocompromised COVID-19 patients
|
| 11.31 - 11.36 |
OP 105 Tenofovir plasma and intracellular pharmacokinetics in INSTI-based regimens
|
| 11.38 - 11.43 |
OP 106 Potent antiviral activity of new generation HIV-1 maturation inhibitors on human primary cells
|
| 11.45 - 11.50 |
OP 107 Evaluation of the in vitro combinatorial activity of Ibalizumab and HIV-1 antivirals
|
Oral Poster
Acute COVID-19 and post COVID-19 syndrome
Oral Poster
Acute COVID-19 and post COVID-19 syndrome
Chairs: M. Lichtner, A. Vergori
| 12.15 - 12.20 |
OP 108 Long-COVID syndrome data from 126,752 patients: a systematic review and meta-analysis
|
| 12.22 - 12.27 |
OP 109 Post-Acute Sequelae of COVID-19 (PASC): An Italian Experience
|
| 12.29 - 12.34 |
OP 110 A multidisciplinary model to screen and treat the post-COVID-19 Syndrome
|
| 12.36 - 12.41 |
OP 111 Long term complications of COVID-19 in patients hospitalized in Clinica Malattie Infettive, Ospedali Riuniti, Ancona
|
| 12.43 - 12.48 |
OP 112 Outcome of patients with chronic liver disease hospitalized for SARS-CoV-2: a single centre matched cohort
|
| 12.50 - 12.55 |
OP 113 Characterization of three waves of covid 19 occurring in southern Italy: results of a multicentre cohort study
|
Oral Poster
Open questions about ART efficacy
Oral Poster
Open questions about ART efficacy
Chairs: S. Arsuffi, M. Borderi
| 13.15 - 13.20 |
OP 120 Blood telomere length gain in virologically suppressed patients switching to dolutegravir plus lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study
|
| 13.22 - 13.27 |
OP 121 Real-life use of Doravirine in treatment-experienced people living with HIV: an Italian multicentre study
|
| 13.29 - 13.34 |
OP 122 Forgiveness to imperfect adherence to bictegravir/emtricitabine/tenofovir alafenamide
|
| 13.36 - 13.41 |
OP 123 Evaluation of metabolic safety profile in naive and virologically suppressed HIV-1 infected individuals starting/switching to a bictegravir single-tablet-regimen in a real-life setting
|
| 13.43 - 13.48 |
OP 124 Real-world effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in women living with HIV: subgroup analysis from ICONA-BIC
|
| 13.50 - 13.55 |
OP 125 Tolerability, viro-immunological, metabolic effects, and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week analysis
|
Oral Poster
Prevention and access to services during COVID pandemic
Oral Poster
Prevention and access to services during COVID pandemic
Chairs: D. Calzavara, N. Gianotti
| 14.20 - 14.25 |
OP 132 Narratives at the time of SARS-CoV-2 vaccination
|
| 14.27 - 14.32 |
OP 133 Vaccine-preventable diseases in PLWH: adherence to recommendations in a single center in Northern Italy
|
| 14.34 - 14.39 |
OP 134 Impact of COVID-19 pandemic on sexual exposure and post-exposure prophylaxis (PEP) prescription appropriateness in a large Hospital, Northern Italy
|
| 14.41 - 14.46 |
OP 135 Looking for 90-90-90 goals: a real life experience during SARS-CoV-2 pandemia
|
| 14.48 - 14.53 |
OP 136 The impact of COVID-19 pandemic on access to HIV services at urban context-based health facilities supported by CUAMM in collaboration with UNICEF, in Beira Mozambique
|
| 14.55 - 15.00 |
OP 137 HAV, HBV and HPV vaccination coverage rate in a community-based pre-exposure prophylaxis program in Milan
|
Oral Poster
Immunopathogenesis of HIV
Oral Poster
Immunopathogenesis of HIV
Chairs: V. Mazzotta, G. Nunnari
| 15.20 - 15.25 |
OP 144 Distinctive features of immune markers of activation and exhaustion in adolescents and young adults people living with HIV infected perinatally vs. adult age
|
| 15.27 - 15.32 |
OP 145 Lack of HIV Type 1 Antibody seroconversion in Acutely Infected Individuals Treated with Early Antiretroviral Therapy
|
| 15.34 - 15.39 |
OP 146 Evaluation of HCMV specific T-cell responses in PLwHIV and their correlation with the immune-virological status and clinical parameters
|
| 15.41 - 15.46 |
OP 147 Crosstalk between gut microbiota and T cell responses in ART-treated HIV-1 infected patients
|
| 15.48 - 15.53 |
OP 148 Large proportion of new HIV diagnoses sustained by non-B subtypes – clinical and immunological correlates
|
Oral Poster
Toxicity of antiretroviral therapy
Oral Poster
Toxicity of antiretroviral therapy
Chairs: C. Gervasoni, R. Gulminetti
| 10.05 - 10.10 |
OP 96 Efficacy and safety of switching to lamivudine/dolutegravir in HIV-1-infected patients aged over 65 years
|
| 10.12 - 10.17 |
OP 97 Specific neurodevelopmental consequences of dolutegravir exposure in a zebrafish embryo model and rescue with early folate treatment
|
| 10.19 - 10.24 |
OP 98 Causes of HIV treatment interruption during the last 20 years: a multi-cohort real-life study
|
| 10.26 - 10.31 |
OP 99 First and second phase viral load decay in real-life using Nonlinear Bayesian Mixed Effect model
|
| 10.33 - 10.38 |
OP 100 The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomized study
|
| 10.40 - 10.45 |
OP 101 Dynamic of lipid profile in HIV naive patients treated by TAF-based regimens: a multicenter observational study
|
Oral Poster
Immunological efficacy of COVID-19 vaccination in vulnerable populations
Oral Poster
Immunological efficacy of COVID-19 vaccination in vulnerable populations
Chairs: G. Scarlatti, M. Tavio
| 12.15 - 12.20 |
OP 114 TNF-alfa expression is negatively correlated to seroconversion after SARS-CoV-2 mRNA BNT162b2 Vaccine in lung transplant patients
|
| 12.22 - 12.27 |
OP 115 Different specific T cell responses to the third dose of mRNA COVID-19 vaccine in multiple sclerosis patients under disease-modifying treatments
|
| 12.29 - 12.34 |
OP 116 SARS-CoV-2 vaccination effectiveness in Pemphigus Vulgaris Rituximab-treated patients
|
| 12.36 - 12.41 |
OP 117 SARS-CoV-2 antibody response in solid organ transplant patients after mRNA BNT162b2: data from an observational prospective study
|
| 12.43 - 12.48 |
OP 118 Durability of SARS-CoV-2 mRNA vaccine immune response in people living with HIV
|
| 12.50 - 12.55 |
OP 119 Decay pattern of Anti–SARS-CoV-2 Antibodies in PWH
|
Oral Poster
Immunological complexity in COVID-19
Oral Poster
Immunological complexity in COVID-19
Chairs: E. Focà , E. Nicastri
| 13.15 - 13.20 |
OP 126 Development of SARS-CoV-2 IgM after 1st vaccine dose predicts longer immunity
|
| 13.22 - 13.27 |
OP 127 Affinity maturation and neutralizing activity of anti-SARS-CoV-2 Spike antibodies
|
| 13.29 - 13.34 |
OP 128 Correlation between clinical aspects and serum/CSF cytokine levels in early versus classic onset SARS-CoV-2-related Guillain-Barré Syndrome
|
| 13.36 - 13.41 |
OP 129 A real-life single-center study on the impact of anti-SARS-CoV2 vaccination
|
| 13.43 - 13.48 |
OP 130 Short course remdesivir in early Covid-19 as an effective and useful option in both out- and in-patients
|
| 13.50 - 13.55 |
OP 131 Dendritic cell maturation after infection with a clone of Leishmania tarentolae expressing the SARS-CoV-2 spike protein as a vaccine vehicle
|
Oral Poster
SARS-CoV-2: from in vivo to in vitro
Oral Poster
SARS-CoV-2: from in vivo to in vitro
Chairs: V. Micheli, M. Santoro
| 14.20 - 14.25 |
OP 138 Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves
|
| 14.27 - 14.32 |
OP 139 Rapid change in epidemiological and clinical characteristics of SARS-CoV-2 circulating variants in Italy in April-December 2021
|
| 14.34 - 14.39 |
OP 140 Higher viral load (VL) in nasopharyngeal swab (NPS) of individuals infected with Omicron BA.2 SARS-CoV-2, compared to Alpha, Gamma, Delta and Omicron BA.1 Variants Of Concern (VOCs)
|
| 14.41 - 14.46 |
OP 141 Dopamine reduces SARS-CoV-2 replication through downregulation of D2 receptors and upregulation of Type-I Interferons
|
| 14.48 - 14.53 |
OP 142 Developmental safety of nirmatrelvir in zebrafish embryos
|
| 14.55 - 15.00 |
OP 143 Peptidomimetic covalent reversible inhibitors exhibit broad-spectrum inhibition of CoVs Main protease and cellular activity against SARS-CoV-2: design, synthesis, biological evaluation, and structural biology
|
Promosso da
Con la sponsorizzazione non condizionante di 
Password dimenticata
Inserisca il suo indirizzo email. Riceverà un messaggio con il link per effettuare il reset della password.
